SCHEMBL5135151

SCHEMBL5135151

CCCCN(Cc1cccc(F)c1F)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.38
HDAC1 Q13547 1/20 0.36
P2RX7 Q99572 2/20 0.36
TSHR P16473 4/20 0.35
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP3A4 P08684 3/20 0.35
HPGD P15428 3/20 0.35
HSD17B10 Q99714 3/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
CRHR1 P34998 2/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
GNRHR P30968 2/20 0.34
ATP4A P20648 2/20 0.34
ATP4B P51164 2/20 0.34
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652221 0.96 C5AR1 (0.42) C5AR1HDAC1P2RX7TSHRKDM4E
SCHEMBL5136240 0.95 C5AR1 (0.39) C5AR1HDAC1P2RX7TSHRKDM4E
SCHEMBL5137572 0.93 C5AR1 (0.39) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5137577 0.89 C5AR1 (0.43) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5137873 0.89 KDM4E (0.38) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5135121 0.88 C5AR1 (0.41) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL647986 0.87 C5AR1 (0.43) C5AR1P2RX7TSHRKDM4EALDH1A1
SCHEMBL5134981 0.87 C5AR1 (0.36) C5AR1HDAC1P2RX7TSHRKDM4E
SCHEMBL5137586 0.86 C5AR1 (0.40) C5AR1HDAC1P2RX7TSHRKDM4E
SCHEMBL650029 0.86 C5AR1 (0.40) C5AR1HDAC1TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed